Claims

1. A planiplaniform transmucosal pharmaceutical administration form which is distinguished by low solubility within the oral cavity and release of active compound which is rapid and constant over a relatively long period, characterized in that it is composed of a solid solution of the active compound

a) in a phosphatidylcholine fraction in which the fatty acid residues are at least 90% saturated, or

b) in a mixture of the phosphatidylcholine fraction specified under a) and a copolymer composed of maleic acid and an alkyl vinyl ether,

and, where appropriate, further pharmaceutically tolerated adjuvants and additives.

2. The administration form as claimed in claim 1, characterized in that it comprises at least 80% by weight of the phosphatidylcholine fraction in accordance with a).

3. The administration form as claimed in claim 1 or 2, characterized in that it comprises polyvinylpyrrolidone as additive.

4. The administration form as claimed in one of claims 1 to 3, characterized in that the active compound is suitable for treating the abuse of addiction-inducing drugs and dependence on these drugs.

5. The administration form as claimed in one or more of claims 1 to 4, characterized in that the active compound is a fused indole derivative and/or its acid addition salt.

6. The administration form as claimed in one or more of claims 1 to 4, characterized in that the active compound is 7-azabicyclo(2.2.1)heptane, 7-azabicyclo(2.2.1)heptene and/or a derivative of this compound.

7. The administration form as claimed in one or more of claims 1 to 4, characterized in that the active compound is ebibatidine and/or a derivative of this compound.

8. The administration form as claimed in one or more of claims 1 to 4, characterized in that the active compound is a benzylidene- and cinnamylidene-annabasiene or a derivative of this compound.

9. The administration form as claimed in one or more of claims 1 to 4, characterized in that the active compound is selected from the compound group mecamylamine, hypericin, CP-52655 and buproprion and/or one of their derivatives.

10. The administration form as claimed in one or more of claims 1 to 4, characterized in that the active compound is selected from the group of oxazolidinone derivatives and befloxatones.

11. The administration form as claimed in one or more of claims 1 to 4, characterized in that the active compound is the cannabinoid receptor (CB 1) antagonist SR 141716.